Qualigen Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
FFR$0.89-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flow
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| For the Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $(4,331,588) | $(3,609,309) |
| Loss from discontinued operations, net of tax | — | (100,000) |
| Loss from continuing operations | $(4,331,588) | $(3,509,309) |
| Adjustments to reconcile loss from continuing operations to net cash used in operating activities: | ||
| Stock-based compensation | 269 | 91,737 |
| Change in fair value of warrant liabilities | (55,199) | (359,906) |
| Gain on voluntary conversion of convertible debt | — | (83,800) |
| Legal expenses deducted from issuance of convertible debt | 20,000 | |
| Provision for credit losses of short-term note receivable | 468,000 | — |
| Accrued interest on short-term note receivable | (251,304) | — |
| Amortization of penalty on promissory note | 179,667 | — |
| Loss on monthly redemptions of convertible debt into common stock | — | 208,852 |
| Accretion of discount on convertible debt | — | 322,717 |
| Loss on issuance of convertible debt | 91,943 | 358,279 |
| Gain on change in fair value of derivative liabilities | — | (174,613) |
| Gain on change in fair value of convertible debt | (37,874) | — |
| Fair value of warrant modification for professional services | — | 9,737 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 1,182,643 | 765,720 |
| Accounts payable | (163,454) | (369,088) |
| Accrued expenses and other current liabilities | 209,390 | 481,556 |
| Net cash used in operating activities | (2,687,507) | (2,258,118) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Issuance of short-term note receivable | (1,518,500) | — |
| Net cash provided by (used in) investing activities - discontinued operations | — | 350,000 |
| Net cash provided by (used in) investing activities | (1,518,500) | 350,000 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from the issuance of convertible debt | 200,000 | 1,475,000 |
| Repayment of convertible debt | (132,000) | — |
| Proceeds from warrant exercises | — | 150,000 |
| Proceeds from issuance of promissory notes | 3,295,000 | — |
| Net cash provided by financing activities - continuing operations | 3,363,000 | 1,625,000 |
| Net cash provided by financing activities - discontinued operations | — | — |
| Net cash provided by financing activities | 3,363,000 | 1,625,000 |
| Net change in cash and cash equivalents | (843,007) | (283,118) |
| Cash and cash equivalents - beginning of period | 1,174,608 | 401,803 |
| Cash and cash equivalents - end of period | $331,601 | $118,685 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||
| Cash paid during the period for: | ||
| Interest | $— | $1,020 |
| Taxes | $— | $2,860 |
| NONCASH FINANCING AND INVESTING ACTIVITIES: | ||
| Voluntary conversion of convertible debt into common stock | $— | $280,200 |
| Monthly redemption of convertible debt into common stock | $— | $903,329 |
| Deemed dividend arising from warrant down-round provision | $1,586 | $60,017 |
| Exchange of derivative liability for warrant and convertible debt | $— | $675,625 |
| Issuance of common stock for the conversion of Series A-2 preferred shares | $2,926,392 | $— |
QUALIGEN THERAPEUTICS, INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.